{"id":"W7108453570","doi":"10.1182/blood-2025-250","title":"Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Panobinostat; Phases of clinical research; Clinical endpoint; Cereblon; Pharmacodynamics; Proteasome inhibitor; Clinical trial; Carfilzomib; Ubiquitin ligase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001017368,0.0009494654,0.001332104,0.0003505356,0.0003783862,0.000821961,0.0006065146,0.0006720322,0.004153247],"category_scores_gemma":[0.000435663,0.0004326552,0.0007027415,0.0004162702,0.0005210901,0.0004397561,0.000276046,0.002206143,0.0008066937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008861789,"about_ca_system_score_gemma":0.001400531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001029344,"about_ca_topic_score_gemma":0.003622169,"domain_scores_codex":[0.9997384,0.00008825587,0.00001597917,0.00005747171,0.00003992149,0.00005994892],"domain_scores_gemma":[0.999713,0.00002897584,0.00005587536,0.00002693977,0.00002409455,0.0001511335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3382414,0.0891683,0.02459625,0.001584856,0.002472386,0.0009578777,0.0004070821,0.005314386,0.3276371,0.0005875044,0.0172865,0.1917463],"study_design_scores_gemma":[0.2781864,0.5849273,0.06167059,0.00008812408,0.001691529,0.001809287,0.0001644791,0.002810272,0.05123525,0.0005346588,0.01680767,0.00007449253],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873337,0.002870868,0.0007130086,0.0004776391,0.0001056541,0.001939867,0.003900175,0.0002099196,0.002449109],"genre_scores_gemma":[0.9800611,0.002769867,0.002233279,0.0008401829,0.00008098131,0.002054982,0.006641113,0.00006018927,0.005258442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004153247,"threshold_uncertainty_score":0.01389402,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04703664611367812,"score_gpt":0.3792228835318142,"score_spread":0.332186237418136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}